EGFR and non-small cell lung carcinoma: In conclusion, by performing a large-scale analysis in 1025 compound EGFR mutation-positive NSCLC patients, we found that different subtypes of compound EGFR mutations were associated with distinct demographic features, co-mutated genes, mutational signatures, and chromosomal instability levels, as well as distinguishing prognosis to first-line EGFR TKIs.